Helix BioPharma Corp (TSX:HBP) (OTCMKTS:HBPCF) CEO Heman Chao tells Proactive the immuno-oncology focused biotech has extended its collaboration with the Florida-based Moffitt Cancer Center for a further year, building on the pair's progress so far.
Chao says Helix and Moffitt have already developed a new pancreatic adenocarcinoma mouse model suitable for testing Helix's lead clinical compound L-DOS47 alone or in combination with immunotherapies.
Price: 0.31 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
Helix BioPharma Corp. (TSX: HBP) Heman Chao presents to investors at the Proactive One2One Virtual Conference. The clinical-stage biopharmaceutical company is developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary...
Industry & services
Clean Seed Capital Group reporting 5.2 million from License...
Health
Prev article
